- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.05. | 5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends | ||
| 09.05. | HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines | ||
| 09.05. | Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales | ||
| 09.05. | NewBiologix licenses cell line technology to Recipharm Advanced Bio | ||
| 09.05. | FDA chief Martin Makary sets June deadline for genAI rollout | ||
| 09.05. | Haya secures $65m in Series A funds to advance heart failure treatment | ||
| 08.05. | Viralgen and Trogenix to progress gene therapy for glioblastoma | ||
| 08.05. | VC firm Vivo Capital outlays $740m for biotech investment | ||
| 08.05. | BioVaxys and Sona partner to develop cancer therapeutics | ||
| 08.05. | ARS Pharma's epinephrine nasal spray 1mg now available in US | ||
| 07.05. | European biotechs must understand US culture while seeking funding | ||
| 07.05. | FDA grants RMAT status to Opus Genetics' OPGx-LCA5 gene therapy | ||
| 07.05. | Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand | ||
| 07.05. | Sarepta shares fall amid FDA's CBER appointment and weak Elevidys sales | ||
| 07.05. | Solve FSHD to invest in Armatus Bio for ARM-201 development | ||
| 07.05. | Expediting parallel drug approval pathways is challenging, but rewarding | ||
| 07.05. | EC approves AstraZeneca's Calquence combo to treat MCL | ||
| 06.05. | Eli Lilly signs $415m deal for Alchemab's ALS therapy | ||
| 06.05. | Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence | ||
| 06.05. | Recursion axes drug programmes to streamline pipeline | ||
| 06.05. | Veraxa and OmniAb to develop bispecific ADC tumour programme | ||
| 06.05. | US government exercises $144m option for smallpox/mpox vaccine contract | ||
| 06.05. | GLP-1 receptor agonists poised to redefine treatment paradigms beyond diabetes and obesity | ||
| 06.05. | Bristol Myers Squibb announces $40bn US investment plan over five years | ||
| 06.05. | Swiss biotech sector's R&D investment grew in 2024 despite global trends |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .